Found: 21
Select item for more details and to access through your institution.
Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1011, doi. 10.1002/cpdd.1436
- By:
- Publication type:
- Article
Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 5, p. 517, doi. 10.1002/cpdd.1389
- By:
- Publication type:
- Article
CCR9 Antagonists in the Treatment of Ulcerative Colitis.
- Published in:
- Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/628340
- By:
- Publication type:
- Article
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women.
- Published in:
- Journal of Bone & Mineral Research, 2005, v. 20, n. 12, p. 2274, doi. 10.1359/jbmr.2005.20.12.2274
- By:
- Publication type:
- Article
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women.
- Published in:
- Journal of Bone & Mineral Research, 2004, v. 19, n. 7, p. 1059, doi. 10.1359/JBMR.040305
- By:
- Publication type:
- Article
The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women.
- Published in:
- Journal of Bone & Mineral Research, 2001, v. 16, n. 2, p. 348, doi. 10.1359/jbmr.2001.16.2.348
- By:
- Publication type:
- Article
Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study.
- Published in:
- Journal of Bone & Mineral Research, 1998, v. 13, n. 6, p. 1032, doi. 10.1359/jbmr.1998.13.6.1032
- By:
- Publication type:
- Article
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0060094
- By:
- Publication type:
- Article
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget’s Disease.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 1998, v. 83, n. 6, p. 1906, doi. 10.1210/jcem.83.6.4871
- By:
- Publication type:
- Article
Risedronate Increases Bone Mass in an Early Postmenopausal Population: Two Years of Treatment Plus One Year of Follow-Up.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 1998, v. 83, n. 2, p. 396, doi. 10.1210/jc.83.2.396
- By:
- Publication type:
- Article
ANCA Associated Vasculitis Subtypes: Response [Letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable.
- Published in:
- European Journal of Haematology, 2003, v. 70, n. 4, p. 263, doi. 10.1034/j.1600-0609.2003.t01-2-00011.x
- By:
- Publication type:
- Article
A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. S3, p. 887, doi. 10.1002/cncr.11138
- By:
- Publication type:
- Article
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study.
- Published in:
- Clinical Kidney Journal, 2022, v. 15, n. 5, p. 922, doi. 10.1093/ckj/sfab294
- By:
- Publication type:
- Article
326. A randomized phase 3 trial evaluating the safety and efficacy of avacopan in patients with new or relapsing ANCA-associated vasculitis.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 11, p. 662, doi. 10.1002/acr2.11185
- By:
- Publication type:
- Article
Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated Vasculitis.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
- Published in:
- PLoS ONE, 2016, v. 11, n. 10, p. 1, doi. 10.1371/journal.pone.0164646
- By:
- Publication type:
- Article
Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2008, v. 35, n. 4, p. 379, doi. 10.1007/s10928-008-9093-5
- By:
- Publication type:
- Article
Effect of Disease Activity at Three and Six Months After Diagnosis on Long‐Term Outcomes in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 5, p. 784, doi. 10.1002/art.40776
- By:
- Publication type:
- Article
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice